Paradoxical Reduction of HDL-C in Diabetes Study
the MPR take:
A recent study found patients with type 2 diabetes treated with fenofibrate and a thiazolidinedione (TZD) were more likely to have extremely low HDL cholesterol (HDL-C). Researchers at Wake Forest University discovered that in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid Trial, those patients assigned to fenofibrate had a 106% higher occurrence of low HDL-C (10.1% fenofibrate vs. 4.9% placebo, P<0.001). Low HDL-C was also associated with concurrent fenofibrate/TZD treatment (7.0% for both vs. 2.2% for neither at 48 months postrandomization). Based on this information, clinicians should be aware of the potential for these treatments to markedly reduce HDL-C levels in patients with type 2 diabetes.
OBJECTIVE: To determine the occurrence of extremely low HDL cholesterol (HDL-C) among participants in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid Trial and to examine the relationship of this finding with treatment with fenofibrate and thiazolidinedione (TZD). RESEARCH ...
READ FULL ARTICLE From care.diabetesjournals.org